![](https://www.diabetesnews.com/wp-content/uploads/2014/04/n-STEM-CELL-D-large570-150x150.jpg)
The results of the phase 3 trial – called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 – sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.